妇外Ⅳ号灌肠剂联合桂枝茯苓胶囊治疗子宫内膜异位症瘀毒互结证临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R711.71

基金项目:

全国中医学术流派传承工作室第二轮建设浙江何氏妇科流派传承工作室建设项目(国中医药人教函[2017]9号);浙江省中医药管理 局项目(2015ZB088)


Clinical Study on Fuwai Ⅳ Enema Combined with Guizhi Fuling Capsules for Endometriosis with Syndrome of Binding of Stasis and Toxin
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察妇外Ⅳ号灌肠剂联合桂枝茯苓胶囊治疗子宫内膜异位症(EM) 瘀毒互结证的临床疗效及其对肿瘤标志物的影响。方法:选取98 例子宫内膜异位症瘀毒互结证患者,将其随机分为2 组各49 例。对照组给予桂枝茯苓胶囊口服治疗,观察组在对照组治疗方案的基础上给予妇外Ⅳ号灌肠剂灌肠治疗。比较2 组治疗前后子宫内膜异位症中医证候积分、痛经视觉模拟评分法(VAS) 评分、临床疗效、不良反应及复发率,以及肿瘤标志物癌抗原(CA125) 含量的差异性。结果:治疗后,观察组平均中医证候积分、痛经VAS 评分均较对照组降低,且随着治疗时间的增加,2 组中医证候积分、疼痛VAS 评分均呈递减趋势,治疗6 个月后中医证候积分、疼痛VAS 评分均最低,差异均有统计学意义(P<0.01)。临床疗效总有效率观察组91.84%明显高于对照组79.59%,差异有统计学意义(P<0.05);对照组总不良反应发生率22.45%,观察组8.16%,但差异无统计学意义(P>0.05);对照组的复发率25.64%,高于观察组的复发率8.89%,但差异无统计学意义(P>0.05)。治疗后,观察组的CA125 水平较对照组显著降低,且随着治疗时间的增加,2 组CA125 含量呈递减趋势,治疗6 个月后CA125 水平均最低(P<0.01)。结论:妇外Ⅳ号灌肠剂联合桂枝茯苓胶囊治疗子宫内膜异位症瘀毒互结证临床疗效良好,可下调肿瘤标志物的水平,不良反应小,复发率低,安全性高,优于单纯桂枝茯苓胶囊口服治疗。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Fuwai Ⅳ enema combined with Guizhi Fuling capsules for endometriosis(EM) with syndrome of binding of stasis and toxin , and its effect on tumor markers. Methods : A total of 98 cases of EM patients with syndrome of binding of stasis and toxin were selected and randomly divided into two groups, 49 cases in each group. The control group was given the oral administration of Guizhi Fuling capsules,and the observation group was additionally given Fuwai Ⅳ enema based on the treatment of the control group. Before and after treatment, Chinese medicine syndrome score of EM,score of Visual Analogue Scale(VAS) of pain,clinical effect,adverse reactions, the recurrence rate,and the differences in content of cancer antigen 125(CA125) as tumor marker were compared between the two groups. Results: After treatment, the average Chinese medicine syndrome score and score of VAS in the observation group were decreased when compared with those in the control group;with the increase of treatment time,the two scores above in the two groups showed a decreasing trend,and the two scores after six- month treatment were the lowest; differences were significant(P<0.01). The total clinical effective rate was 91.84% in the observation group, significantly higher than that of 79.59% in the control group,the difference being significant(P<0.05). The total incidence of adverse reactions was 22.45% in the control group,and 8.16% in the observation group,but there was no significance in the difference(P>0.05). The recurrence rate was 25.64% in the control group, higher than that of 8.89% in the observation group, but there was no significance in the difference(P>0.05). After treatment, level of CA125 in the observation group was significantly decreased when compared with that in the control group;with the increase of treatment time,the levels in the two groups showed a decreasing trend, and and the two levels after six- month treatment were the lowest(P<0.01). Conclusion:The therapy of Fuwai Ⅳ enema combined with Guizhi Fuling capsules has a good clinical effect in the treatment of endometriosis with syndrome of binding of stasis and toxin. It can down- regulate levels of tumor markers, with few adverse reactions,low recurrence rate,and high safety. The therapy is better than simple oral administration of Guizhi Fuling capsules.

    参考文献
    相似文献
    引证文献
引用本文

方晓红.妇外Ⅳ号灌肠剂联合桂枝茯苓胶囊治疗子宫内膜异位症瘀毒互结证临床研究[J].新中医,2021,53(16):116-120

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-08-23
  • 出版日期: